Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer.
drug delivery system
nanoplatforms
oral squamous cell carcinoma
treatment of oral cancer
tumor targeted therapy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
10
2020
accepted:
30
11
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
epublish
Résumé
Oral cancers refer to malignant tumors associated with high morbidity and mortality, and oral squamous cell carcinoma accounts for the majority of cases. It is an important part of head and neck, and oral cancer is one of the six most common cancers in the world. At present, the traditional treatment methods for oral cancer include surgery, radiation therapy, and chemotherapy. However, these methods have many disadvantages. In recent years, nanomedicine, the delivery of drugs through nanoplatforms for the treatment of cancer, has become a promising substitutive therapy. The use of nanoplatforms can reduce the degradation of the drug in the body and accurately deliver it to the tumor site. This minimizes the distribution of the drug to other organs, thereby reducing its toxicity and allowing higher drug concentration at the tumor site. This review introduces polymer nanoparticles, lipid-based nanoparticles, metal nanoparticles, hydrogels, exosomes, and dendrimers for the treatment of oral cancer, and discusses how these nanoplatforms play an anti-cancer effect. Finally, the review gives a slight outlook on the future prospects of nanoplatforms for oral cancer treatment.
Identifiants
pubmed: 33391000
doi: 10.3389/fphar.2020.616101
pii: 616101
pmc: PMC7773899
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
616101Informations de copyright
Copyright © 2020 Zhao, Li, Wu, Wang, Ma and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chem Soc Rev. 2019 Jul 15;48(14):3771-3810
pubmed: 31165801
Int J Oncol. 2014 Dec;45(6):2439-45
pubmed: 25230791
Chem Commun (Camb). 2014 Nov 25;50(91):14071-81
pubmed: 24955443
Methods Enzymol. 2009;464:105-29
pubmed: 19903552
Nanomedicine (Lond). 2016 Nov;11(22):2959-2973
pubmed: 27781559
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
Adv Mater. 2017 Aug;29(32):
pubmed: 28632302
Aging (Albany NY). 2020 Apr 20;12(8):6756-6773
pubmed: 32310826
Int J Pharm. 2017 Jun 15;525(1):21-31
pubmed: 28412450
J Photochem Photobiol B. 2009 Feb 9;94(2):143-6
pubmed: 19097802
Oral Dis. 2020 Jul 13;:
pubmed: 32657515
Adv Drug Deliv Rev. 2017 Dec 1;122:20-30
pubmed: 28257998
Int J Pharm. 2019 Feb 25;557:178-181
pubmed: 30597261
Nanomedicine (Lond). 2020 Mar;15(7):661-676
pubmed: 32141806
Cell Biochem Biophys. 2014 Jul;69(3):663-72
pubmed: 24563116
Nanomedicine (Lond). 2020 Jul;15(16):1585-1597
pubmed: 32669025
Int J Pharm. 2011 Mar 15;406(1-2):163-72
pubmed: 21219990
Cancer Treat Rev. 1999 Apr;25(2):83-101
pubmed: 10395834
Semin Cell Dev Biol. 2015 Apr;40:82-8
pubmed: 25765629
Eur J Pharm Biopharm. 2008 Oct;70(2):633-40
pubmed: 18577447
Cancer Sci. 2013 Mar;104(3):369-74
pubmed: 23216802
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
ACS Nano. 2015 Jul 28;9(7):6985-95
pubmed: 26022907
Adv Drug Deliv Rev. 2013 Jan;65(1):21-3
pubmed: 22580334
Drug Discov Today. 2015 May;20(5):536-47
pubmed: 25555748
Sci Rep. 2019 Jan 24;9(1):663
pubmed: 30679544
Mol Pharm. 2018 Sep 4;15(9):3601-3602
pubmed: 30176732
Colloids Surf B Biointerfaces. 2016 Nov 1;147:65-72
pubmed: 27490455
J Extracell Vesicles. 2015 Apr 20;4:26316
pubmed: 25899407
Int J Nanomedicine. 2011;6:2749-55
pubmed: 22131825
ACS Nano. 2014 May 27;8(5):4530-8
pubmed: 24754567
Adv Drug Deliv Rev. 2004 Jan 13;56(1):17-30
pubmed: 14706443
Theranostics. 2019 Feb 20;9(5):1426-1452
pubmed: 30867842
Br Dent J. 2009 Nov 28;207(10):471-5
pubmed: 19946320
J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8
pubmed: 16046478
Nanomedicine. 2018 Jan;14(1):1-12
pubmed: 28882675
Semin Nephrol. 2003 Sep;23(5):460-4
pubmed: 13680535
Am J Cancer Res. 2020 Jan 01;10(1):350-364
pubmed: 32064172
J Control Release. 2014 Jan 28;174:137-42
pubmed: 24280262
Blood. 2009 Feb 26;113(9):1977-81
pubmed: 19064723
Colloids Surf B Biointerfaces. 2011 Jul 1;85(2):262-9
pubmed: 21435845
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
J Pharm Sci. 2007 Oct;96(10):2547-65
pubmed: 17688284
Cancer Chemother Pharmacol. 2016 Jun;77(6):1103-24
pubmed: 26886018
Lancet Oncol. 2012 Dec;13(12):1234-41
pubmed: 23153506
Eur J Pharm Biopharm. 2015 Jun;93:52-79
pubmed: 25813885
Blood. 2007 Nov 1;110(9):3234-44
pubmed: 17666571
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Adolesc Young Adult Oncol. 2018 Oct;7(5):546-552
pubmed: 30239252
J Nanobiotechnology. 2015 Oct 01;13:63
pubmed: 26427800
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84
pubmed: 20661737
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Ann R Coll Surg Engl. 1995 Sep;77(5):325-31
pubmed: 7486755
Recent Pat Nanotechnol. 2013 Jan;7(1):41-55
pubmed: 22946628
Int J Mol Sci. 2016 Aug 31;17(9):
pubmed: 27589733
Eur J Pharm Sci. 2009 Nov 5;38(4):405-13
pubmed: 19765652
Biochem Pharmacol. 2012 Apr 15;83(8):1104-11
pubmed: 22285912
ACS Nano. 2013 Nov 26;7(11):9896-904
pubmed: 24083505
Int J Cancer. 2007 May 15;120(10):2262-70
pubmed: 17290400
Sci Rep. 2014 Dec 23;4:7583
pubmed: 25533220
Cell Mol Biol Lett. 2005;10(3):455-70
pubmed: 16217556
J Nanobiotechnology. 2018 Oct 16;16(1):81
pubmed: 30326899
CA Cancer J Clin. 1995 Nov-Dec;45(6):352-68
pubmed: 7583907
J Colloid Interface Sci. 2017 Jan 15;486:112-120
pubmed: 27697648
Curr Treat Options Oncol. 2012 Mar;13(1):35-46
pubmed: 22252884
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):329-35
pubmed: 22990112
Adv Sci (Weinh). 2018 Jun 19;5(6):1800811
pubmed: 29938194
Expert Opin Drug Deliv. 2012 May;9(5):497-508
pubmed: 22439808
Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72
pubmed: 15109768
Biomater Sci. 2019 Dec 1;7(12):5270-5282
pubmed: 31603446
Med Hypotheses. 2019 Aug;129:109241
pubmed: 31371076
Nat Commun. 2017 Feb 13;8:14292
pubmed: 28194032
Mini Rev Med Chem. 2019;19(1):3-11
pubmed: 30179131
Opt Express. 2003 Jun 16;11(12):1385-91
pubmed: 19466009
J Clin Med. 2019 Dec 02;8(12):
pubmed: 31810241
Pharmacol Ther. 2020 Feb;206:107447
pubmed: 31756363
Oral Oncol. 2003 Sep;39(6):601-9
pubmed: 12798404
Conf Proc IEEE Eng Med Biol Soc. 2004;2004:1210-3
pubmed: 17271905
Expert Opin Drug Deliv. 2014 Sep;11(9):1449-70
pubmed: 24870351
Int J Nanomedicine. 2010 Mar 09;5:117-28
pubmed: 20309398
Nanomedicine (Lond). 2017 Feb;12(4):295-315
pubmed: 28093940
Am J Nephrol. 1994;14(2):81-4
pubmed: 8080010
J Control Release. 2015 Dec 10;219:396-405
pubmed: 26241750
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Adv Mater. 2015 Jan 21;27(3):576-85
pubmed: 25238634
Oral Oncol. 2009 Apr-May;45(4-5):454-60
pubmed: 18804412
Immunol Cell Biol. 2015 Sep;93(8):727-34
pubmed: 25776846
Expert Opin Drug Deliv. 2018 Aug;15(8):771-785
pubmed: 30064267
Small. 2019 Jan;15(4):e1804131
pubmed: 30565431
J Oral Maxillofac Surg. 2011 Sep;69(9):2452-9
pubmed: 21684654
J Nanobiotechnology. 2011 Nov 28;9:55
pubmed: 22123084
Acta Biomater. 2017 Jul 15;57:251-261
pubmed: 28438704
Clin Med Insights Ther. 2013;2013(5):
pubmed: 24273416
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
Adv Sci (Weinh). 2019 Jun 21;6(17):1900101
pubmed: 31508270
Med Hypotheses. 2008;70(5):1041-3
pubmed: 17910995
ACS Nano. 2016 Nov 22;10(11):10049-10057
pubmed: 27934074
Mater Sci Eng C Mater Biol Appl. 2015 Oct;55:471-81
pubmed: 26117779
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Asian J Pharm Sci. 2020 Jul;15(4):397-415
pubmed: 32952666
Int J Pharm. 2004 Jan 9;269(1):1-14
pubmed: 14698571
Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504
pubmed: 17532091
PLoS One. 2012;7(4):e33860
pubmed: 22529899
Biomaterials. 2014 Aug;35(26):7647-53
pubmed: 24920436
Expert Opin Drug Deliv. 2013 Mar;10(3):397-409
pubmed: 23289421
Eur J Pharm Biopharm. 2016 Feb;99:73-83
pubmed: 26690333
Arch Oral Biol. 2019 Jul;103:47-54
pubmed: 31132617
Oncology (Williston Park). 2017 Mar 15;31(3):198-208
pubmed: 28299757
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Cancer Res. 2003 May 1;63(9):1999-2004
pubmed: 12727808
Adv Healthc Mater. 2017 Dec;6(23):
pubmed: 28945012
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Drug Discov Today. 2014 Apr;19(4):474-81
pubmed: 24140592
Curr Med Chem. 2011;18(14):2086-102
pubmed: 21517767